Genetically engineered immune cells wipe out lupus in mice

first_img Lupus can be a stubborn disease to treat. Although many struck by the autoimmune condition live relatively normal lives, some suffer from kidney failure, blood clots, and other complications that can be deadly. Now, scientists have found that a novel treatment that wipes out the immune system’s B cells cures mice of the condition. Though the work is preliminary, it has excited researchers because it uses a therapy already approved for people with blood cancer.“This is a critical stepping stone,” says Jennifer Anolik, a rheumatologist who runs the lupus clinic at the University of Rochester Medical Center in New York who was not involved with the work.The strategy is known as chimeric antigen receptor (CAR)-T therapy. It involves genetically engineering T cells, the sentries of the immune system, so they recognize and destroy certain cells in the body. Although it comes with potentially serious side effects, it can be lifesaving. The approach took the cancer world by storm in 2011, after scientists reported saving patients with an advanced form of leukemia. Since then, it has been approved to treat certain leukemias in children and lymphomas in adults. Although CAR-T therapy can target different cells, the approved treatments hunt down and destroy B cells by spotting a protein marker, CD19, that almost all B cells sport on their surface. 3D4Medical/Science Source Click to view the privacy policy. Required fields are indicated by an asterisk (*) By Jennifer Couzin-FrankelMar. 6, 2019 , 2:00 PM Destroying B cells, like the one shown here, helped mice with lupus revert to good health. Genetically engineered immune cells wipe out lupus in micecenter_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Email Sign up for our daily newsletter Get more great content like this delivered right to you! Country Since CAR-T therapy emerged, scientists who study autoimmune diseases have eyed it with interest because B cells are involved in many of these diseases. B cells can release autoantibodies that damage the body’s tissue and provoke T cells into attacks on tissues as well. In 2016, a team at the University of Pennsylvania reported that mice with a rare autoimmune disease called pemphigus vulgaris were helped by CAR-T therapy.But lupus has presented a puzzle. An antibody called rituximab, which depletes B cells and is often prescribed to patients with rheumatoid arthritis and multiple sclerosis, failed to help many people with lupus in two large clinical trials. That “caused a bit of head-scratching,” says Marko Radic, an immunologist at the University of Tennessee Health Science Center in Memphis.Did the results mean B cells weren’t important in lupus after all? The answer is no, suggests Mark Shlomchik, an immunologist at the University of Pittsburgh in Pennsylvania who was not involved in the new study. He believes rituximab stumbled in part because of an unfortunate confluence of how the antibody works and how the immune system falters in lupus. Rituximab needs immune cells called macrophages to step in and assist in B cell destruction. That works in some diseases, but in lupus, those cells can be “paralyzed,” says Shlomchik, and struggle to pull this off.Enter CAR-T therapy, where T cells become efficient B cell slayers without needing a helping hand. Radic and his colleagues tested the approach in two mouse models of lupus. After the mice got sick, the team exposed them to whole-body radiation to wipe out existing immune cells. (People getting CAR-T therapy receive chemotherapy for the same purpose.) Then, the scientists infused the genetically altered T cells into 41 animals.In 26 of the mice, the CAR-T cells successfully destroyed the B cells with CD19—nearly all of them—and those cells never reappeared. That’s similar to what’s been observed in cancer patients who undergo CAR-T therapy. The effects on mouse health surprised even Radic, who’d had high hopes: The animals’ spleens, skin, kidneys, and other body parts showed no remaining signs of lupus, the team reports today in Science Translational Medicine. “We were so impressed,” Radic says.Most of the animals that were successfully treated lived for more than a year after treatment, a long stretch in mouse-time. Animals that got placebo therapy all died within 8 to 10 months, and many perished earlier.Anolik says she would like to better understand why CAR-T therapy didn’t work for 15 mice. But she’s hopeful for the treatment’s future for her patients and others.The findings are “very compelling,” Shlomchik says. In some patients, lupus is “as aggressive as cancer,” he says, so even a drastic treatment could make sense.last_img read more